KR960022476A - 디페닐 디설파이드 화합물 - Google Patents
디페닐 디설파이드 화합물 Download PDFInfo
- Publication number
- KR960022476A KR960022476A KR1019950056107A KR19950056107A KR960022476A KR 960022476 A KR960022476 A KR 960022476A KR 1019950056107 A KR1019950056107 A KR 1019950056107A KR 19950056107 A KR19950056107 A KR 19950056107A KR 960022476 A KR960022476 A KR 960022476A
- Authority
- KR
- South Korea
- Prior art keywords
- heterocyclic group
- membered heterocyclic
- pharmaceutical composition
- amino
- composition according
- Prior art date
Links
- GUUVPOWQJOLRAS-UHFFFAOYSA-N diphenyl disulphide Natural products C=1C=CC=CC=1SSC1=CC=CC=C1 GUUVPOWQJOLRAS-UHFFFAOYSA-N 0.000 title claims abstract 4
- -1 Diphenyl disulfide compound Chemical class 0.000 title claims abstract 3
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 claims abstract 2
- 102000003777 Interleukin-1 beta Human genes 0.000 claims abstract 2
- 108090000193 Interleukin-1 beta Proteins 0.000 claims abstract 2
- 206010040047 Sepsis Diseases 0.000 claims abstract 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract 2
- 230000001684 chronic effect Effects 0.000 claims abstract 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 7
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 7
- 125000003277 amino group Chemical group 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229940012413 factor vii Drugs 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
본 발명은 만성 류마티스 및 패혈증과 같은 질병의 치료 또는 예방에 유용한 인터류킨-1β(IL-1β)의 생성 및 종양 괴사 인자∝(TNF∝)의 방출을 억제하는 활성을 갖는 신규한 디페닐 디설파이드 화합물에 관한 것이다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (9)
- 하기 일반식(Ⅰ)의 디페닌 디설파이드 화합물 및 약제학적으로 허용되는 이의 염.상기 식에서, R1는 헤테로원자로서 두 개의 질소 원자를 함유하는 5- 또는 6-원 헤테로사이클릭 그룹; 페닐 환과 축합된 상기 5-또는 6-헤테로사이클릭 그룹; 아미노 그룹; 또는 헤테로 원자로서 두 개의 질소 원자를 함유하는 5-또는 6-원 헤테로사이크릭 그룹에 의해서 또는 페닐환과 축합된 상기 5-또는 6원 헤테로 사이클릭 그룹에 의해서 일-치환된 아미노 그룹이고, R2는 헤테로원자로서 두 개의 질소 원자를 함유하는 5-또는 6-원 헤테로사이클릭 그룹; 페닐환과 축합된 상기 5- 또는 6-원 헤테로사이클릭 그룹; 아미노 그룹; 헤테로 원자로서 두 개의 질소 원자를 함유하는 5- 또는 6-원 헤테로사이클릭 그룹에 의해서 또는 페닐환과 축합된 상기 5- 또는 6-원 헤테로사이클릭 그룹에 의해서 일-치환된 아미노 그룹; 또는 니트로 그룹이며, R3및 R4는 동일하거나 상이하고; 각각 수소 원자; 탄소원자수 1 내지 4의 알킬 그룹; 탄소원자수 1 내지 4의 알콕시 그룹; 아미노 그룹; 또는 니트로 그룹일 수 있고, 단, R1이 아미노 그룹일 때, R2는 아미노 또는 니트로 그룹이 아니다
- 제1항에 있어서, 하기 구조식을 갖는 화합물
- 제1항에 있어서, 하기 구조식을 갖는 화합물.
- 제1항에 있어서, 하기 구조식을 갖는 화합물.
- 활성성분으로서 제1항의 디페닐 디설파이드 혼합물 또는 약제학적으로 허용되는 이의 염 및 약제학적으로 허용되는 담체를 포함하는 약제학적 조성물.
- 제5항에 있어서, 인터류긴-1β의 생성 억제제로서 사용되는 약제학적 조성물.
- 제5항에 있어서, 종양 괴사 인자 α의 방출 억제제로서 사용되는 약제학적 조성물.
- 제5항에 있어서, 만성 류마티스 치료용 약물로서 사용되는 약제학적 조성물.
- 제5항에 있어서, 패혈증 치료용 약물로서 사용되는 약제학적 조성물.※ 참고사항:최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP94-322072 | 1994-12-26 | ||
| JP32207294 | 1994-12-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR960022476A true KR960022476A (ko) | 1996-07-18 |
Family
ID=18139609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019950056107A KR960022476A (ko) | 1994-12-26 | 1995-12-26 | 디페닐 디설파이드 화합물 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US5698564A (ko) |
| EP (1) | EP0720983B1 (ko) |
| KR (1) | KR960022476A (ko) |
| CA (1) | CA2165918A1 (ko) |
| DE (1) | DE69520345T2 (ko) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2894445B2 (ja) * | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Ｃｅｔｐ活性阻害剤として有効な化合物 |
| AU1753299A (en) * | 1997-11-05 | 1999-05-31 | Schering Aktiengesellschaft | N,n'-substituted carbamides used as a medicament |
| CA2299247A1 (en) * | 2000-02-25 | 2001-08-25 | Felix J. Baerlocher | Sulfur containing compounds |
| EP1603554A1 (en) * | 2003-03-17 | 2005-12-14 | Japan Tobacco Inc. | Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate |
| US20040225018A1 (en) * | 2003-03-17 | 2004-11-11 | Japan Tobacco Inc. | Pharmaceutical compositions of CETP inhibitors |
| TWI393560B (zh) * | 2003-05-02 | 2013-04-21 | Japan Tobacco Inc | 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合 |
| EP1742635B1 (en) | 2004-04-20 | 2018-03-07 | Acea Biosciences, Inc. | Substituted organosulfur compounds and methods of using thereof |
| ATE421547T1 (de) * | 2004-12-22 | 2009-02-15 | California Inst Of Techn | Abbaubare polymere und herstellungsverfahren dafür |
| CA3137752A1 (en) * | 2019-05-02 | 2020-11-05 | Thiolab, Llc, | Inhibition of il-1 and il-6 inflammation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04128276A (ja) * | 1990-09-19 | 1992-04-28 | Pfizer Pharmaceut Co Ltd | アミノベンゾサルタム誘導体およびその用途 |
| DE4305080A1 (de) * | 1993-02-19 | 1994-08-25 | Asta Medica Ag | Neues Verfahren zur Herstellung von Azaphenothiazinen |
-
1995
- 1995-12-21 CA CA002165918A patent/CA2165918A1/en not_active Abandoned
- 1995-12-21 DE DE69520345T patent/DE69520345T2/de not_active Expired - Fee Related
- 1995-12-21 US US08/576,681 patent/US5698564A/en not_active Expired - Fee Related
- 1995-12-21 EP EP95120328A patent/EP0720983B1/en not_active Expired - Lifetime
- 1995-12-26 KR KR1019950056107A patent/KR960022476A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DE69520345D1 (de) | 2001-04-19 |
| CA2165918A1 (en) | 1996-06-27 |
| US5698564A (en) | 1997-12-16 |
| DE69520345T2 (de) | 2001-09-06 |
| EP0720983B1 (en) | 2001-03-14 |
| EP0720983A1 (en) | 1996-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU95108387A (ru) | Дикетопиперазин, способ его получения, фармацевтическая композиция, применение дикетопиперазина | |
| ES2197160T3 (es) | Antagonistas fibronogeno bicicliclos. | |
| DK0874824T3 (da) | Trisubstituerede phenylderivater nyttige som PDE IV inhibitorer | |
| ES555653A0 (es) | Un procedimiento para preparar compuestos imidazoheterociclicos | |
| DE3853577D1 (de) | Benzyliden-Malononitril-Derivate zur Hemmung von proliferativen Prozessen in Säugetierzellen. | |
| KR910006277A (ko) | N-치환된-4-피리미딘아민 및 피리미딘디아민, 이의 제조방법 및 약제로서의 이의 용도 | |
| DE69023928D1 (de) | DIAMINVERBINDUNGEN UND ARZNEIMITTEL GEGEN CEREBRALE STöRUNGEN DIE DIESE ENTHALTEN. | |
| EA200000614A1 (ru) | 2,3-замещенные соединения индола в качестве ингибиторов сох-2 | |
| KR910007883A (ko) | 퀴놀린 유도체, 그의 제조방법 및 용도 | |
| KR960022476A (ko) | 디페닐 디설파이드 화합물 | |
| DK457286D0 (da) | Fluorenforbindelse og farmaceutisk praeparat indeholdende en saadan forbindelse | |
| ATE67193T1 (de) | 6-phenyl-pyridazin-verbindungen. | |
| KR930701446A (ko) | 트리사이클릭 벤조디아제핀 유도체, 그의 제조방법 및 이를 함유하는 약제학적 조성물 | |
| DK0659193T3 (da) | Blodpladeaggregationsinhibitorer | |
| KR890016017A (ko) | 치환된 1-(1h-이미다졸-4-일)알킬-벤즈아미드 | |
| KR950702554A (ko) | 소염제로서 유용한 2-헤테로시클릭-5-히드록시-1,3-피리미딘 (2-Heterocyclic-5-Hydroxy-1,3-Pyrimidines Useful as Antiinflammatory Agents) | |
| KR950702544A (ko) | 비페닐메탄 유도체 및 이를 함유하는 약제 | |
| RU95110868A (ru) | Новые конденсированные производные тиазола, способ его получения и его фармацевтическая композиция | |
| ATE27455T1 (de) | Heterocyclische guanidino-phenylamidine, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung. | |
| KR870006043A (ko) | 피라진유도체 그 제조방법 및 약제조성물 | |
| EA200200682A1 (ru) | Новые соединения n-бензилпиперазина, способ их получения и фармацевтические композиции, их содержащие | |
| KR960021021A (ko) | 인터루킨-1β의 생성 및 종양 괴사 인자 α의 방출을 억제하기 위한 약제 | |
| CA2296586A1 (en) | New 2,3-benzodiazepine derivatives | |
| KR910006217A (ko) | 디히드로카페인산 유도체 및 이를 함유하는 약학제제 | |
| ES2010225A6 (es) | Procedimiento de preparacion de nuevos derivados de piperazina diona-2,6. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |